I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Gritti, G.
217
results:
Search for persons
X
Format
Online (217)
Mediatypes
Articles (Online) (115)
Bookchapter (Online) (1)
OpenAccess-fulltext (101)
Languages
english (202)
more...
french (1)
portuguese (5)
italian (2)
less...
Sorted by: Relevance
Sorted by: Year
?
1
Exposure to obinutuzumab does not affect outcomes of SARS‐C..:
Pinto, A.
;
Caltagirone, M.
;
Battista, M.
...
British Journal of Haematology. , 2024
Link:
https://doi.org/10.1111/..
?
2
SAKK 38/19: ASSESSING A CTDNA AND PET‐ORIENTED THERAPY IN P..:
Stathis, A.
;
Hitz, F.
;
Schär, S.
...
Hematological Oncology. 41 (2023) S2 - p. 165-166 , 2023
Link:
https://doi.org/10.1002/..
?
3
GLOFITAMAB PLUS POLATUZUMAB VEDOTIN DEMONSTRATES DURABLE RE..:
Hutchings, M.
;
Avigdor, A.
;
Sureda, A.
...
Hematological Oncology. 41 (2023) S2 - p. 138-140 , 2023
Link:
https://doi.org/10.1002/..
?
4
COMBINING CD19‐4‐1BBL (RO7227166) WITH GLOFITAMAB IS SAFE A..:
Hutchings, M.
;
Dickinson, M.
;
Carlo‐Stella, C.
...
Hematological Oncology. 41 (2023) S2 - p. 136-138 , 2023
Link:
https://doi.org/10.1002/..
?
5
Duvelisib in patients with relapsed/refractory peripheral T..:
Mehta‐Shah, N.
;
Jacobsen, E. D.
;
Zinzani, P. L.
...
Hematological Oncology. 41 (2023) S2 - p. 499-500 , 2023
Link:
https://doi.org/10.1002/..
?
6
P1239: TISLELIZUMAB, A PD-1 INHIBITOR FOR RELAPSED/REFRACTO..:
Bachy, E.
;
Savage, K. J.
;
Huang, H.
...
HemaSphere. 6 (2022) - p. 1124-1125 , 2022
Link:
https://doi.org/10.1097/..
?
7
P1172: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIP..:
Zinzani, P. L.
;
Zain, J.
;
Mead, M.
...
HemaSphere. 6 (2022) - p. 1058-1059 , 2022
Link:
https://doi.org/10.1097/..
?
8
Skip pattern approach toward the early access of innovative..:
Apolone, G.
;
Ardizzoni, A.
;
Biondi, A.
...
ESMO Open. 6 (2021) 4 - p. 100227 , 2021
Link:
https://doi.org/10.1016/..
?
9
POLATUZUMAB VEDOTIN + OBINUTUZUMAB + VENETOCLAX IN PATIENTS..:
Bannerji, R.
;
Yuen, S.
;
Phillips, T.
...
Hematological Oncology. 39 (2021) S2 - p. , 2021
Link:
https://doi.org/10.1002/..
?
10
NIVOLUMAB PLUS BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY ..:
Zinzani, P. L.
;
Santoro, A.
;
Gritti, G.
...
Hematological Oncology. 39 (2021) S2 - p. , 2021
Link:
https://doi.org/10.1002/..
?
11
A NON‐INTERVENTIONAL STUDY OF OBINUTUZUMAB IN PATIENTS WITH..:
., A
;
. Zinzani, P. L
;
. Arcaini, L
...
Hematological Oncology. 39 (2021) S2 - p. , 2021
Link:
https://doi.org/10.1002/..
?
12
DEVELOPMENT AND VALIDATION OF A PET RADIOMICS PROGNOSTIC MO..:
Ceriani, L
;
Milan, L
;
Cascione, L
...
Hematological Oncology. 39 (2021) S2 - p. , 2021
Link:
https://doi.org/10.1002/..
?
13
Chimeric antigen receptor T cells for gamma–delta T cell ma..:
Wawrzyniecka, P. A.
;
Ibrahim, L.
;
Gritti, G.
..
Leukemia. 36 (2021) 2 - p. 577-579 , 2021
Link:
https://doi.org/10.1038/..
?
14
NIVOLUMAB COMBINED WITH BRENTUXIMAB VEDOTIN FOR RELAPSED/RE..:
Zinzani, P.L.
;
Santoro, A.
;
Gritti, G.
...
Hematological Oncology. 37 (2019) S2 - p. 157-158 , 2019
Link:
https://doi.org/10.1002/..
?
15
DURABILITY OF COMPLETE RESPONSE AFTER BLINATUMOMAB THERAPY ..:
Viardot, A.
;
Hess, G.
;
Bargou, R.
...
Hematological Oncology. 37 (2019) S2 - p. 429-430 , 2019
Link:
https://doi.org/10.1002/..
1-15